EDIT · Company research
Editas Medicine, Inc. Common Stock (EDIT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) stock price, news, quote and history - Yahoo Finance UK | Editas Medicine, Inc. (EDIT) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 15, 2026 | neutral | 0 | 0.6 |
| Record your Mac’s screen, then edit and share the videos in seconds - Cult of Mac | Record your Mac’s screen, then edit and share the videos in seconds Cult of Mac | View source ↗ | Cult of Mac | Oct 15, 2026 | neutral | 0 | 0.6 |
| A delivery method generated engineered immune cells inside the body and depleted B cells. - Stock Titan | A delivery method generated engineered immune cells inside the body and depleted B cells. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift - Seeking Alpha | Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift Seeking Alpha | View source ↗ | Seeking Alpha | Oct 12, 2026 | neutral | 0 | 0.6 |
| Editas Medicine, Inc. (EDIT) stock price, news, quote and history - Yahoo Finance Australia | Editas Medicine, Inc. (EDIT) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 9, 2026 | neutral | 0 | 0.6 |
| Editas Medicine, Inc. (EDIT) Stock Price, News, Quote & History - Yahoo! Finance Canada | Editas Medicine, Inc. (EDIT) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| EDIT Set to Begin First-in-Human Study in Hypercholesterolemia | Editas Medicine announced approval to initiate the Strive phase I/II clinical study of EDIT-401, an investigational in vivo gene-editing therapy for heterozygous familial hypercholesterolemia (HeFH) in Australia. The single-dose therapy demonstrated approximately 90% or greater reductions in atherogenic lipoproteins in preclinical primate studies. Patient dosing is planned for 2026 with initial safety data expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Wells Fargo Upgrades Editas Medicine (EDIT) on Phase 1/2 Trial A - GuruFocus | Wells Fargo Upgrades Editas Medicine (EDIT) on Phase 1/2 Trial A GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Editas wins Australia nod for gene editing trial (EDIT:NASDAQ) - Seeking Alpha | Editas wins Australia nod for gene editing trial (EDIT:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 8, 2026 | neutral | 0 | 0.6 |
| An experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 months - Stock Titan | An experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 months Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Editas Medicine (EDIT) Institutional Ownership 2026 $EDIT - MarketBeat | Editas Medicine (EDIT) Institutional Ownership 2026 $EDIT MarketBeat | View source ↗ | MarketBeat | Oct 8, 2026 | neutral | 0 | 0.6 |
| CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? - Stocktwits | CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| Editas Medicine (EDIT) Slides 2.15% to $2.73 as Shares Drift Toward Lower Support - Swing Entry Signals - https://www.siam.in/ | Editas Medicine (EDIT) Slides 2.15% to $2.73 as Shares Drift Toward Lower Support - Swing Entry Signals https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 7, 2026 | neutral | 0 | 0.6 |
| Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Consensus Price Target of $5.80 According to Analysts - MarketBeat | Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Consensus Price Target of $5.80 According to Analysts MarketBeat | View source ↗ | MarketBeat | Oct 5, 2026 | neutral | 0 | 0.6 |
| Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50-Day Moving Average - Here's Why - MarketBeat | Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50-Day Moving Average - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 1, 2026 | neutral | 0 | 0.6 |
| Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions - Simply Wall Street | Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 23, 2026 | neutral | 0 | 0.6 |
| Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ) - Seeking Alpha | Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 23, 2026 | neutral | 0 | 0.6 |
| $EDIT stock is down 10% today. Here's what we see in our data. - Quiver Quantitative | $EDIT stock is down 10% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 9, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.